New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: For the treatment of adult patients with resectable stage II, IIIA, or IIIB (T3–4N2) non–small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery: Reimbursement Recommendation [Internet].​Pembrolizumab (Keytruda): Indication: For the treatment of adult patients with resectable stage II, IIIA, or IIIB (T3–4N2) non–small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery: Reimbursement Recommendation [Internet].